Sanofi - Aventis Groupe: Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH's plenary and late-breaking sessions

Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH's plenary and late-breaking

Related Keywords

Paris ,France General ,France ,United States ,America ,American ,Eva Schaefer Jansen ,Arnaud Delepine ,Felix Lauscher ,Nathalie Pham ,Dietmar Berger ,Sally Bain ,American Society Of Hematology ,Global Head Of Development ,Alnylam Pharmaceutical Inc ,American Society ,Late Breaking Abstract Session ,Plenary Scientific Session ,Global Head ,Alnylam Pharmaceutical ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Sanofi ,Eventis ,Roupe ,Data ,Rom ,Hase ,Studies ,Emonstrating ,Fitusiran ,Ignificantly ,Educed ,Leeds ,People ,Hemophilia ,Without ,Inhibitors ,Were ,Featured ,Plenary ,Gate ,Breaking ,Session ,